Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes

I. Caroline Crocker, Martin K. Church, S. Edet Ohia, Robert G. Townley

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)151-160
Number of pages10
JournalInternational Archives of Allergy and Immunology
Volume121
Issue number2
StatePublished - 2000

Fingerprint

Beclomethasone
Phosphoric Diester Hydrolases
Human Activities
T-Lymphocytes
Cyclic AMP
Interleukin-2
Th2 Cells
Phosphodiesterase Inhibitors
Glucocorticoids
Anti-Inflammatory Agents
Cell Line
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes. / Crocker, I. Caroline; Church, Martin K.; Ohia, S. Edet; Townley, Robert G.

In: International Archives of Allergy and Immunology, Vol. 121, No. 2, 2000, p. 151-160.

Research output: Contribution to journalArticle

Crocker, I. Caroline ; Church, Martin K. ; Ohia, S. Edet ; Townley, Robert G. / Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes. In: International Archives of Allergy and Immunology. 2000 ; Vol. 121, No. 2. pp. 151-160.
@article{7c1d64ff64aa415386daefd33812a43b,
title = "Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes",
abstract = "Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.",
author = "Crocker, {I. Caroline} and Church, {Martin K.} and Ohia, {S. Edet} and Townley, {Robert G.}",
year = "2000",
language = "English",
volume = "121",
pages = "151--160",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes

AU - Crocker, I. Caroline

AU - Church, Martin K.

AU - Ohia, S. Edet

AU - Townley, Robert G.

PY - 2000

Y1 - 2000

N2 - Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.

AB - Background: We recently reported that CD4+ T cells that have been activated in vivo or in vitro contain elevated cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE) activity. Since both phosphodiesterase inhibitors and glucocorticoids have anti-inflammatory activity, we sought to investigate the effect of beclomethasone on PDE activity. Methods: PDE activity was measured in CD4+ T cells after 24 h of culture with beclomethasone. Cells were obtained from the peripheral blood of nonatopic persons (nCells), pre-seasonal (pCells), seasonal (within the first 2 weeks; sCells) and mid-seasonal (mCells) allergic rhinitics and asymptomatic allergic asthmatics (aCells). In addition, the effect of beclomethasone on Th2 cell lines and cells that had been activated in vitro with PHA or interleukin (IL)-2 was determined. Results: PDE activity was decreased in a concentration-dependent manner by incubation of mCells, Th2 lines and PHA or IL-2-activated CD4+ T cells with beclomethasone (p <0.05). However, beclomethasone did not modulate PDE activity in nCells, pCells, sCells, or aCells. Conclusions: Beclomethasone only decreases cAMP PDE activity in CD4+ T cells when it is increased by cell activation either in vitro or in vivo. Copyright (C) 2000 S. Karger AG, Basel.

UR - http://www.scopus.com/inward/record.url?scp=0034051937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034051937&partnerID=8YFLogxK

M3 - Article

VL - 121

SP - 151

EP - 160

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 2

ER -